Sirgo Mark A Form 4 March 17, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

SECURITIES

1(b).

(Print or Type Responses)

may continue.

See Instruction

1. Name and Address of Reporting Person **
Sirgo Mark A

2. Issuer Name **and** Ticker or Trading Symbol

BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI] Issuer
(Check all applicable)

5. Relationship of Reporting Person(s) to

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

(Last)

(First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year) 02/21/2011

X Director _____ 10% Owner X_ Officer (give title _____ Other (specify

President and CEO

C/O BIODELIVERY SCIENCES INTL, INC., 801 CORPORATE

(Zip)

CENTER DRIVE, SUITE 210

(Street)

(State)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed (Month/Day/Year)

X Form filed by One Reporting Person
___ Form filed by More than One Reporting

Persor

Table I. Non-Daningtine Committee Assumed Disposed of an Dansfield Commed

below)

RALEIGH, NC 27607

(City)

(- 3)	(******)	1 abie	e I - Non-Do	erivative s	Securi	ties Acq	juirea, Disposea o	i, or Beneficial	ly Owned
1.Title of Security		2. Transaction Date 2A. Deemed 3. 4. Securities Acque Month/Day/Year) Execution Date, if Transaction(A) or Disposed on Control (B)				5. Amount of Securities	Form: Direct	Indirect	
(Instr. 3)		any (Month/Day/Year)	Code (Instr. 8)	(D) (Instr. 3, 4 and 5)		Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	03/15/2011		P	2,130	A		829,162	D	
Common Stock	03/15/2011		P	900	A	\$ 3.28	830,062	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Edgar Filing: Sirgo Mark A - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 3.55	02/21/2011		A	22,369	<u>(1)</u>	02/25/2021	Common Stock	22,369

Reporting Owners

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
Sirgo Mark A					
C/O BIODELIVERY SCIENCES INTL, INC.	X	President			
801 CORPORATE CENTER DRIVE, SUITE 210	Λ		and CEO		
RALEIGH, NC 27607					

Signatures

/s/ Mark A.
Sirgo

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- One third of the options granted herein will vest and be exercisable on each of the following dates, February 25, 2012, February 25, 2013 and February 25, 2014, subject to the condition that the reporting person is employed by the Issuer on each of the respective dates.
- (2) Not applicable. Such options were granted by Issuer's Board of Directors as compensation for serving as President and Chief Executive Officer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2